Notably, Yu et al. 7 indicated that the expression of HER2 was not correlated with the density of interstitial CTLA-4+ lymphocytes in breast cancer patients, while HER2 was independent predictors of shorter OS and disease-free survival (DFS). Here, ERBB2 is linked to breast carcinoma.